Antonela Sofía Asad

Antonela Sofía Asad

Auto-generated profile, based on publicly available information

Antonela Sofía Asad

Instituto de Investigaciones Biomédicas (INBIOMED, UBA-CONICET), Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2018 in Immunotherapy
Verified
Journal Article
Closed access
NKNeha Kamran
Neha Kamran
MAMahmoud S Alghamri
Mahmoud S Alghamri
FNFelipe J Nunez
Felipe J Nunez
DSDiana Shah
Diana Shah
AAAntonela S Asad
Antonela S Asad
MCMaria G. Castro
Maria G. Castro
There is a large unmet need for effective therapeutic approaches for glioma, the most malignant brain tumor. Clinical and preclinical studies have enormously expanded our knowledge about the molecular aspects of this deadly disease and its interaction with the host immune system. In this review we highlight the wide array of immunotherapeutic interventions that are currently being tested in glioma patients. Given the molecular heterogeneity, tumor immunoediting and the profound immunosuppression that characterize glioma, it has become clear that combinatorial approaches targeting multiple pathways tailored to the genetic signature of the tumor will be required in order to achieve optimal therapeutic efficacy.

27 July 2016 in Expert Opinion on Biological Therapy
Verified
Journal Article
Open access
NKNeha Kamran
Neha Kamran
ACAlexandra Calinescu
Alexandra Calinescu
MCMarianela Candolfi
Marianela Candolfi
MCMayuri Chandran
Mayuri Chandran
YMYohei Mineharu
Yohei Mineharu
MCMaria G. Castro
Maria G. Castro
Introduction: Outcome for glioma (GBM) remains dismal despite advances in therapeutic interventions including chemotherapy, radiotherapy and surgical resection. The overall survival benefit observed with immunotherapies in cancers such as melanoma and prostate cancer has fuelled research into evaluating immunotherapies for GBM. Areas covered: Preclinical studies have brought a wealth of information for improving the prognosis of GBM and multiple clinical studies are evaluating a wide array of immunotherapies for GBM patients. This review highlights advances in the development of immunotherapeutic approaches. We discuss the strategies and outcomes of active and passive immunotherapies for GBM including vaccination strategies, gene therapy, check point blockade and adoptive T cell therapies. We also focus on immunoediting and tumor neoantigens that can impact the efficacy of immunotherapies. Expert opinion: Encouraging results have been observed with immunotherapeutic strategies; some clinical trials are reaching phase III. Significant progress has been made in unraveling the molecular and genetic heterogeneity of GBM and its implications to disease prognosis. There is now consensus related to the critical need to incorporate tumor heterogeneity into the design of therapeutic approaches. Recent data also indicates that an efficacious treatment strategy will need to be combinatorial and personalized to the tumor genetic signature.

12 June 2017 in Expert Opinion on Biological Therapy
Verified
Journal Article
Closed access
AAAntonela S. Asad
Antonela S. Asad
MAMariela A. Moreno Ayala
Mariela A. Moreno Ayala
MGM. Florencia Gottardo
M. Florencia Gottardo
CZCamila Zuccato
Camila Zuccato
ACAlejandro Javier Nicola Candia
Alejandro Javier Nicola Candia
MCMarianela Candolfi
Marianela Candolfi
Introduction: Breast cancer is the most common cancer in women all over the world. Furthermore, up to one third of breast tumors develop metastases that are resistant to standard therapies. Gene therapeutic strategies have been developed in order to specifically target cancer cells either directly or through the stimulation of antitumor immunity. Areas covered: This review describes the therapeutic strategies that are currently under development to treat this disease using engineered viral vectors including: adenovirus, adeno-associated virus, lentivirus, poxvirus, reovirus, baculovirus, herpesvirus and oncolytic viruses. Advantages and disadvantages of these multiple gene therapy platforms are discussed in detail. Expert opinion: Metastatic breast cancer is a perfect candidate for gene therapy approaches due to the presence of several tumor antigens and the aberrant expression of many molecular pathways. Oncolytic vectors are able to attack tumor cells while sparing normal cells and their activity is often enhanced by the administration of chemotherapy. However, more efforts are needed in order to reduce toxicity and to achieve better transduction efficiency. Improved preclinical models and a more critical patient selection for clinical trials, along with advances in gene therapy regulations, will surely facilitate the evolution of gene therapy for the treatment of metastatic breast cancer.

24 December 2018 in Expert Opinion on Therapeutic Targets
Verified
Journal Article
Closed access
CZCamila Florencia Zuccato
Camila Florencia Zuccato
AAAntonela Sofia Asad
Antonela Sofia Asad
ACAlejandro Javier Nicola Candia
Alejandro Javier Nicola Candia
MGMaría Florencia Gottardo
María Florencia Gottardo
MAMariela Alejandra Moreno Ayala
Mariela Alejandra Moreno Ayala
MCMarianela Candolfi
Marianela Candolfi
Introduction: Mitochondrial-derived peptides (MDPs) are encoded within the mitochondrial genome. They signal within the cell or are released to act as autocrine/paracrine/endocrine cytoprotective factors playing a key role in the cellular stress response. The first reported and better characterized MDP is humanin (HN), which exerts robust protective effects against a myriad of cytotoxic stimuli in many cell types. These effects have led to the evaluation of HN and its analogs as therapeutic targets for several chronic diseases. Areas covered: We describe the latest findings on the mechanism of action of HN and discuss the role of HN as therapeutic target for neurodegenerative and cardiovascular diseases, diabetes, male infertility, and cancer. Since HN can be detected in circulation, we also depict its value as a biomarker for these diseases. Expert opinion: HN analogs and peptide mimetics have been developed over the last decade and show promising results in preclinical models of degenerative diseases. Local administration of gene therapy vectors that overexpress or silence endogenous HN could also hold therapeutic potential. Controversy on the role of HN in cancer progression and chemoresistance should be addressed before the translation of these therapeutic approaches.

29 July 2017 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
MAMariela A. Moreno Ayala
Mariela A. Moreno Ayala
MGMaría Florencia Gottardo
María Florencia Gottardo
MIMercedes Imsen
Mercedes Imsen
AAAntonela S. Asad
Antonela S. Asad
EJElisa Bal de Kier Joffé
Elisa Bal de Kier Joffé
MCMarianela Candolfi
Marianela Candolfi

20 December 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
AAAntonela Sofía Asad
Antonela Sofía Asad
ACAlejandro Javier Nicola Candia
Alejandro Javier Nicola Candia
NGNazareno Gonzalez
Nazareno Gonzalez
CZCamila Florencia Zuccato
Camila Florencia Zuccato
AAAraceli Abt
Araceli Abt
MCMarianela Candolfi
Marianela Candolfi
Although prolactin (PRL) and its receptor (PRLR) have been detected in glioblastoma multiforme (GBM), their role in its pathogenesis remains unclear. Our aim was to explore their contribution in GBM pathogenesis. We detected PRL and PRLR in all GBM cell lines tested. PRLR activation or overexpression using plasmid transfection increased proliferation, viability, clonogenicity, chemoresistance and matrix metalloproteinase activity in GBM cells, while PRLR antagonist ∆1–9-G129R-hPRL reduced their proliferation, viability, chemoresistance and migration. Meta-analysis of transcriptomic data indicated that PRLR was expressed in all grade II-III glioma (GII-III) and GBM samples. PRL was upregulated in GBM biopsies when compared to GII-III. While in the general population tumour PRL/PRLR expression did not correlate with patient survival, biological sex-stratified analyses revealed that male patients with PRL+/PRLRHIGH GBM performed worse than PRL+/PRLRLOW GBM. In contrast, all male PRL+/PRLRHIGH GII-III patients were alive whereas only 30% of PRL+/PRLRLOW GII-III patients survived after 100 months. Our study suggests that PRLR may be involved in GBM pathogenesis and could constitute a therapeutic target for its treatment. Our findings also support the notion that sexual dimorphism should be taken into account to improve the care of GBM patients.